1. Joel S. Schuman

    0 Comments Related Articles

    1. Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Joel S. Schuman

    Joel S. Schuman

    Joel S. Schuman is the Chairman of  the Department of Ophthalmology at the NYU Langone Medical Center, New York University School of Medicine.

  3. Quotes

    1. It's the most rapidly adopted ophthalmic technology in history.
      In How OCT innovations changing glaucoma care
    2. OCT will be able to detect glaucomatous abnormalities prior to our current functional measurement technology being able to detect them, and the earlier in the disease that you can detect damage or progression, the more likely it is you are able to prevent further progression with less intensive intervention.
      In Emerging technologies open new horizons in glaucoma structural evaluation, management
    3. I’m delighted by the Champalimaud Foundation’s recognition of our efforts...We continue to work on improving OCT and in the next decade, it could be as portable and easy to use as a standard ophthalmoscope.
      In Joel S. Schuman, M.D., Part of Team Receiving António Champalimaud Vision Award
    4. That gives the promise to better track progression to detect change over time, and that is really a big advance in terms of changes from time-domain OCT.
      In OCT devices increasingly finding use outside retinal practice
    5. You can look for characteristic nerve fiber layer abnormalities that are seen in glaucoma and these will show up as arcuate abnormalities — deviations from normal — on the deviation map of the spectral-domain OCT.
      In OCT devices increasingly finding use outside retinal practice
    6. With imaging we have much younger technology. The progression assessments with these technologies seem to be more sensitive than functional assessment, but they don't necessarily overlap with functional assessment or even with each other.
      In Better Glaucoma Progression Tracking
    7. I think that in future iterations we will be able to have focal assessment of change, looking at the overall trend as in regression, but also looking at event analysis, analogous to the GPA on visual field.
      In Better Glaucoma Progression Tracking